Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1839 1
1951 3
1952 1
1961 1
1963 1
1964 2
1966 1
1968 1
1969 1
1972 1
1973 2
1975 1
1977 2
1978 1
1981 1
1982 1
1986 3
1988 2
1990 1
1992 2
1994 2
1996 2
1997 7
1999 2
2000 2
2001 2
2002 3
2003 2
2004 4
2005 1
2007 1
2008 4
2009 6
2010 13
2011 14
2012 47
2013 25
2014 20
2015 45
2016 23
2017 18
2018 9
2019 15
2020 10
2021 9
2022 11
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Results by year

Filters applied: . Clear all
Page 1
Four distinct trajectories of tau deposition identified in Alzheimer's disease.
Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y; Alzheimer’s Disease Neuroimaging Initiative; Pontecorvo MJ, Devous MD, Rabinovici GD, Alexander DC, Lyoo CH, Evans AC, Hansson O. Vogel JW, et al. Nat Med. 2021 May;27(5):871-881. doi: 10.1038/s41591-021-01309-6. Epub 2021 Apr 29. Nat Med. 2021. PMID: 33927414 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression.
Wen J, Fu CHY, Tosun D, Veturi Y, Yang Z, Abdulkadir A, Mamourian E, Srinivasan D, Skampardoni I, Singh A, Nawani H, Bao J, Erus G, Shou H, Habes M, Doshi J, Varol E, Mackin RS, Sotiras A, Fan Y, Saykin AJ, Sheline YI, Shen L, Ritchie MD, Wolk DA, Albert M, Resnick SM, Davatzikos C; iSTAGING consortium, ADNI, BIOCARD, and BLSA. Wen J, et al. JAMA Psychiatry. 2022 May 1;79(5):464-474. doi: 10.1001/jamapsychiatry.2022.0020. JAMA Psychiatry. 2022. PMID: 35262657 Free PMC article.
Deep learning-based polygenic risk analysis for Alzheimer's disease prediction.
Zhou X, Chen Y, Ip FCF, Jiang Y, Cao H, Lv G, Zhong H, Chen J, Ye T, Chen Y, Zhang Y, Ma S, Lo RMN, Tong EPS; Alzheimer’s Disease Neuroimaging Initiative; Mok VCT, Kwok TCY, Guo Q, Mok KY, Shoai M, Hardy J, Chen L, Fu AKY, Ip NY. Zhou X, et al. Commun Med (Lond). 2023 Apr 6;3(1):49. doi: 10.1038/s43856-023-00269-x. Commun Med (Lond). 2023. PMID: 37024668 Free PMC article.
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease.
Jiang Y, Zhou X, Wong HY, Ouyang L, Ip FCF, Chau VMN, Lau SF, Wu W, Wong DYK, Seo H, Fu WY, Lai NCH, Chen Y, Chen Y, Tong EPS; Alzheimer’s Disease Neuroimaging Initiative; Mok VCT, Kwok TCY, Mok KY, Shoai M, Lehallier B, Losada PM, O'Brien E, Porter T, Laws SM, Hardy J, Wyss-Coray T, Masters CL, Fu AKY, Ip NY. Jiang Y, et al. Nat Aging. 2022 Jul;2(7):616-634. doi: 10.1038/s43587-022-00241-9. Epub 2022 Jul 15. Nat Aging. 2022. PMID: 37117777 Free PMC article.
Polygenic effects on the risk of Alzheimer's disease in the Japanese population.
Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T; Alzheimer’s Disease Neuroimaging Initiative; Japanese Alzheimer’s Disease Neuroimaging Initiative. Kikuchi M, et al. Alzheimers Res Ther. 2024 Feb 27;16(1):45. doi: 10.1186/s13195-024-01414-x. Alzheimers Res Ther. 2024. PMID: 38414085 Free PMC article.
Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease.
Erickson P, Simrén J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H; ADNI Cohort. Erickson P, et al. JAMA Neurol. 2023 Jul 31;80(9):969-79. doi: 10.1001/jamaneurol.2023.2338. Online ahead of print. JAMA Neurol. 2023. PMID: 37523162 Free PMC article.
Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of 18F-FDG-PET.
Zhang Q, Fan C, Wang L, Li T, Wang M, Han Y, Jiang J; and for the Alzheimer’s Disease Neuroimaging Initiative. Zhang Q, et al. Geroscience. 2024 Feb;46(1):1407-1420. doi: 10.1007/s11357-023-00897-0. Epub 2023 Aug 23. Geroscience. 2024. PMID: 37610594 Free PMC article.
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease.
Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D; Alzheimer’s Disease Neuroimaging Initiative; Strandberg O, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Smith R, Stomrud E, Ossenkoppele R, Hansson O. Pichet Binette A, et al. Nat Commun. 2022 Nov 4;13(1):6635. doi: 10.1038/s41467-022-34129-4. Nat Commun. 2022. PMID: 36333294 Free PMC article.
306 results